



DuPont Central Research
and Development

8EHQ-1096-13759

(A)

DuPont Central Research
and Development
Haskell Laboratory for Toxicology
and Industrial Medicine
P.O. Box 50, Elkton Road
Newark, DE 19714-0050
Fax: (302) 366-5207

October 8, 1996



8EHQ-96-13759

EXPRESS MAIL- RETURN RECEIPT REQUESTED

Document Processing Center (TS-790)
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U. S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460

CSRAD/DPPT
RECEIVED
12/4/96

56 OCT 21 AM 11:07

RECEIVED

Dear 8(e) Coordinator:

**Propanenitrile, 2,3-dichloro-
CAS Number 2601-89-0**

This letter is to inform you of the results of a dermal sensitization study (The Murine Local Lymph Node Assay) with the above-referenced substance. The study was conducted using female CBA/JHsd mice.

Test animals (6 per concentration) were topically induced on both ears for 3 consecutive days with the test substance in DMSO/acetone at concentrations of 0.5%, 1%, and 2.5%. The same procedures were carried out on contemporaneous control groups except that the test substance was replaced by DMSO/acetone (vehicle control) or 25% hexylcinnamaldehyde (positive control). Animals were then injected with radiolabel and the proliferation in the draining lymph nodes (auricular) of the ears was assessed.

The stimulation index (the mean dpm value of the test substance group divided by the mean dpm value of the vehicle control group) was ≥ 3.0 at all dose levels in the study. Statistical significance was observed for the dpm data in all dose groups and a monotone dose response was evident. Under the conditions of this study, it was concluded that the above referenced compound has the potential to be a dermal sensitizer.

The effects described above are being reported in accordance with the guidance given in the EPA TSCA Section 8(e) Reporting Guide (June 1991).

Sincerely,

Charles F. Reinhardt
For CFR

Charles F. Reinhardt, M.D.
Director



8897000009

CFR/GL:jmg
(302)366-5285

Triage of 8(e) Submissions

Date sent to triage: 12/18/96

NON-CAP

CAP

Submission number: 13759 A

TSCA Inventory: **Y N D**

Study type (circle appropriate):

Group 1 - Gordon Cash (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX **SEN** w/NEUR

Group 3 - HERD (1 copy each)

STOX CTOX EPI RTOX GTOX

STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

- This is the original 8(e) submission; refile after triage evaluation.
- This original submission has been split; rejoin after triage evaluation.
- Other:

Photocopies Needed for Triage Evaluation

entire document: 0 1 2 3

front section and CECATS: 0 1 2 3

Initials: _____

Date: _____

DECATSVIRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # BEHQ: 1096-13759 SEQ: A

TYPE: INT SUPP FLWP

SUBMITTER NAME: DuPont

INFORMATION REQUESTED: FLWP DATE: _____
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)
 DISPOSITION:
 (6539) REFER TO CHEMICAL SCREENING
 0578 CAP NOTICE

SUB DATE: 10-8-96 OTS DATE: 10-21-96 CSRAD DATE: 12-4-96

CHEMICAL NAME: propanenitrile, 2,3-dichloro- CASE# 2601-89-0

VOLUNTARY ACTIONS
 0401 NO ACTION REPORTED
 0402 STUDIES PLANNED/IN PROGRESS
 0403 NOTIFICATION OF WORKING STATUS
 0404 LABEL/MSDS CHANGES
 0405 PROGRESS/STATUS CHANGES
 0406 APP/USE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPICLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEMPHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCCUR/EL/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY	01 02 04	0248 PROD/USE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PRODCOMP/CHEM ID	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0299 OTHER	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0229 METAB/PHARMAO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMAO (HUMAN)	01 02 04		

TRIALGE DATA: NON-CBL INVENTORY: ONGOING REVIEW: SPECIES WUS TOXICOLOGICAL CONCERN: USE: PRODUCTION:

CAS SR YES NO (IN PROGRAM) YES (DROPPED) NO (CONTINUE) REPORTER HIGH MED LOW

USAGENTS

“13759A”=“M”=“DERMAL SENSITIZATION IN MICE IS OF MEDIUM CONCERN. MICE (6/CONCENTRATION) WERE TOPICALLY INDUCED ON BOTH EARS FOR 3 CONSECUTIVE DAYS WITH TEST MIXTURE IN DMSO/ACETONE AT CONCENTRATIONS OF 0.5%, 1.0%, OR 2.5% FOLLOWING THE MURINE LOCAL LYMPH NODE ASSAY TESTING PROTOCOL. PROLIFERATION IN THE DRAINING LYMPH NODES WAS ASSESSED FOLLOWING INJECTION OF RADIOACTIVE IODODEOXYURIDINE. THE STIMULATION INDEX(TEST/CONTROL RATIO) WAS GREATER THAN OR EQUAL TO 3 AT ALL DOSE LEVELS. THE TEST SUBSTANCE WAS CONCLUDED TO HAVE THE POTENTIAL TO BE A DERMAL SENSITIZER.”